<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238416</url>
  </required_header>
  <id_info>
    <org_study_id>IEC-08/2019-1336</org_study_id>
    <nct_id>NCT04238416</nct_id>
  </id_info>
  <brief_title>Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF</brief_title>
  <acronym>BCAA-ACLF</acronym>
  <official_title>Efficacy of Lactulose Plus Intravenous Branched Chain Amino Acids Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Prospective Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study analyses the effect of intravenous branched chain amino acids (BCAA) on overt HE
      in patients with ACLF. The investigators plan to study the efficacy of combining intravenous
      BCAA with lactulose versus lactulose alone in the medical management of overt HE in patients
      with ACLF and its impact on overall survival and improvement in grade of HE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute on chronic liver failure (ACLF) is a distinct clinical entity in the spectrum of
      chronic liver disease associated with high short term mortality. Hepatic encephalopathy (HE)
      is commonly seen in patients with ACLF and its treatment mainly involves non-absorbable
      disaccharides (lactulose/lactitol).Treatment of HE in ACLF is based on extrapolation of data
      available from cirrhotic patients. No studies have compared different treatment options for
      HE in patients with ACLF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective interventional cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Survival</measure>
    <time_frame>At day day 28</time_frame>
    <description>All cause Mortality assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of encephalopathy by ≥ 1 grade</measure>
    <time_frame>72 hours</time_frame>
    <description>Improvement in hepatic encephalopathy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in level of ammonia</measure>
    <time_frame>48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of consciousness recovery time among survivors</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolongation of time to death among non-survivors</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention/reduction of cerebral edema based on optic nerve sheath diameter</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Acute-On-Chronic Liver Failure</condition>
  <arm_group>
    <arm_group_label>IV BCAA + Lactulose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Branched Chain Amino Acids - 500mL once daily for 3 days plus Lactulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactulose alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Lactulose alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Branched chain amino acid</intervention_name>
    <description>Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm</description>
    <arm_group_label>IV BCAA + Lactulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactulose</intervention_name>
    <description>Oral lactulose will be given to patients in both arms</description>
    <arm_group_label>IV BCAA + Lactulose</arm_group_label>
    <arm_group_label>Lactulose alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75 years

          2. Either gender

          3. Patients with ACLF (CANONIC definition) of any aetiology with HE ≥grade 2 as per
             West-Haven Criteria

        Exclusion Criteria:

          1. Those who do not consent to participate in the study

          2. Patients with structural brain lesions or stroke

          3. Inability to obtain informed consent from patient or relatives

          4. Severe preexisting cardiopulmonary disease

          5. Renal dysfunction (S. Creatinine ≥ 2mg/dL)

          6. Pregnancy/Lactation

          7. Post liver transplant patients

          8. HIV infection

          9. Patients who are on psychoactive drugs, like sedatives or antidepressants

         10. Patients who are too sick to carry out the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhumita Premkumar, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Madhumita Premkumar, MD, DM</last_name>
    <phone>+919540951061</phone>
    <email>drmadhumitap@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhumita Premkumar, MD, DM</last_name>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011 Apr;54(4):640-9. doi: 10.1016/j.jhep.2010.07.045. Epub 2010 Dec 1.</citation>
    <PMID>21163546</PMID>
  </reference>
  <reference>
    <citation>Donovan JP, Schafer DF, Shaw BW Jr, Sorrell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet. 1998 Mar 7;351(9104):719-21.</citation>
    <PMID>9504517</PMID>
  </reference>
  <reference>
    <citation>Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology. 2006 Oct;44(4):788-94. Review.</citation>
    <PMID>17006913</PMID>
  </reference>
  <reference>
    <citation>Norenberg MD, Martinez-Hernandez A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res. 1979 Feb 2;161(2):303-10.</citation>
    <PMID>31966</PMID>
  </reference>
  <reference>
    <citation>Albrecht J, Dolińska M, Hilgier W, Lipkowski AW, Nowacki J. Modulation of glutamine uptake and phosphate-activated glutaminase activity in rat brain mitochondria by amino acids and their synthetic analogues. Neurochem Int. 2000 Apr;36(4-5):341-7.</citation>
    <PMID>10733001</PMID>
  </reference>
  <reference>
    <citation>Laake JH, Takumi Y, Eidet J, Torgner IA, Roberg B, Kvamme E, Ottersen OP. Postembedding immunogold labelling reveals subcellular localization and pathway-specific enrichment of phosphate activated glutaminase in rat cerebellum. Neuroscience. 1999;88(4):1137-51.</citation>
    <PMID>10336125</PMID>
  </reference>
  <reference>
    <citation>Cordoba J, Ventura-Cots M, Simón-Talero M, Amorós À, Pavesi M, Vilstrup H, Angeli P, Domenicali M, Ginés P, Bernardi M, Arroyo V; CANONIC Study Investigators of EASL-CLIF Consortium. Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). J Hepatol. 2014 Feb;60(2):275-81. doi: 10.1016/j.jhep.2013.10.004. Epub 2013 Oct 12.</citation>
    <PMID>24128414</PMID>
  </reference>
  <results_reference>
    <citation>Fischer JE, Rosen HM, Ebeid AM, James JH, Keane JM, Soeters PB. The effect of normalization of plasma amino acids on hepatic encephalopathy in man. Surgery. 1976 Jul;80(1):77-91.</citation>
    <PMID>818729</PMID>
  </results_reference>
  <results_reference>
    <citation>Dam G, Aamann L, Vistrup H, Gluud LL. The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy. J Clin Exp Hepatol. 2018 Dec;8(4):448-451. doi: 10.1016/j.jceh.2018.06.004. Epub 2018 Jun 27. Review.</citation>
    <PMID>30568347</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossi-Fanelli F, Riggio O, Cangiano C, Cascino A, De Conciliis D, Merli M, Stortoni M, Giunchi G. Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Dig Dis Sci. 1982 Oct;27(10):929-35.</citation>
    <PMID>6749458</PMID>
  </results_reference>
  <results_reference>
    <citation>Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H. Branched-chain amino acids for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2015 Feb 25;(2):CD001939. doi: 10.1002/14651858.CD001939.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(9):CD001939.</citation>
    <PMID>25715177</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Madhumita Premkumar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>branched chain amino acids</keyword>
  <keyword>hepatic encephalopathy</keyword>
  <keyword>lactulose</keyword>
  <keyword>acute on chronic liver failure</keyword>
  <keyword>bispectral index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

